Literature DB >> 12079782

Structure of TAR RNA complexed with a Tat-TAR interaction nanomolar inhibitor that was identified by computational screening.

Zhihua Du1, Kenneth E Lind, Thomas L James.   

Abstract

HIV-1 TAR RNA functions critically in viral replication by binding the transactivating regulatory protein Tat. We recently identified several compounds that experimentally inhibit the Tat-TAR interaction completely at a 100 nM concentration. We used computational screening of the 181,000-compound Available Chemicals Directory against the three-dimensional structure of TAR [1]. Here we report the NMR-derived structure of TAR complexed with acetylpromazine. This structure represents a new class of compounds with good bioavailability and low toxicity that bind with high affinity to TAR. NMR data unambiguously show that acetylpromazine binds only to the unique 5' bulge site to which the Tat protein binds. Specificity and affinity of binding are conferred primarily by a network of base stacking and hydrophobic interactions. Acetylpromazine alters the structure of free TAR less than Tat peptides and neomycin do.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12079782     DOI: 10.1016/s1074-5521(02)00151-5

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  34 in total

1.  Solution structure of the HIV-1 frameshift inducing stem-loop RNA.

Authors:  David W Staple; Samuel E Butcher
Journal:  Nucleic Acids Res       Date:  2003-08-01       Impact factor: 16.971

2.  LNA/DNA chimeric oligomers mimic RNA aptamers targeted to the TAR RNA element of HIV-1.

Authors:  Fabien Darfeuille; Jens Bo Hansen; Henrik Orum; Carmelo Di Primo; Jean-Jacques Toulmé
Journal:  Nucleic Acids Res       Date:  2004-06-04       Impact factor: 16.971

3.  Validation of an empirical RNA-ligand scoring function for fast flexible docking using Ribodock.

Authors:  S David Morley; Mohammad Afshar
Journal:  J Comput Aided Mol Des       Date:  2004-03       Impact factor: 3.686

4.  Evidence that electrostatic interactions dictate the ligand-induced arrest of RNA global flexibility.

Authors:  Stephen W Pitt; Qi Zhang; Dinshaw J Patel; Hashim M Al-Hashimi
Journal:  Angew Chem Int Ed Engl       Date:  2005-05-30       Impact factor: 15.336

5.  Conformational dynamics of RNA-peptide binding: a molecular dynamics simulation study.

Authors:  Yuguang Mu; Gerhard Stock
Journal:  Biophys J       Date:  2005-10-20       Impact factor: 4.033

6.  Impact of static and dynamic A-form heterogeneity on the determination of RNA global structural dynamics using NMR residual dipolar couplings.

Authors:  Catherine Musselman; Stephen W Pitt; Kush Gulati; Lesley L Foster; Ioan Andricioaei; Hashim M Al-Hashimi
Journal:  J Biomol NMR       Date:  2006-11-01       Impact factor: 2.835

7.  The concept of template-based de novo design from drug-derived molecular fragments and its application to TAR RNA.

Authors:  Andreas Schüller; Marcel Suhartono; Uli Fechner; Yusuf Tanrikulu; Sven Breitung; Ute Scheffer; Michael W Göbel; Gisbert Schneider
Journal:  J Comput Aided Mol Des       Date:  2007-12-07       Impact factor: 3.686

8.  Probing Na(+)-induced changes in the HIV-1 TAR conformational dynamics using NMR residual dipolar couplings: new insights into the role of counterions and electrostatic interactions in adaptive recognition.

Authors:  Anette Casiano-Negroni; Xiaoyan Sun; Hashim M Al-Hashimi
Journal:  Biochemistry       Date:  2007-05-09       Impact factor: 3.162

9.  Characterizing the relative orientation and dynamics of RNA A-form helices using NMR residual dipolar couplings.

Authors:  Maximillian H Bailor; Catherine Musselman; Alexandar L Hansen; Kush Gulati; Dinshaw J Patel; Hashim M Al-Hashimi
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

10.  Discovery of ligands for a novel target, the human telomerase RNA, based on flexible-target virtual screening and NMR.

Authors:  Irene Gómez Pinto; Christophe Guilbert; Nikolai B Ulyanov; Jay Stearns; Thomas L James
Journal:  J Med Chem       Date:  2008-11-27       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.